CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF
Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR 4 activity.
1 .- 68 . (canceled)
69 . A compound having a structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
z1 is 3;
R 3 is halogen or —OR 3A ; wherein R 3A is hydrogen; and
R 7 is substituted or unsubstituted alkyl.
70 . The compound of claim 69 , wherein R 7 is a substituted alkyl.
71 . The compound of claim 70 , wherein R 7 is a substituted C 1 -C 4 alkyl.
72 . The compound of claim 71 , wherein R 7 is —CH 2 CH 2 OH.
73 . A method of treating cancer mediated by C—C chemokine receptor type 4 (CCR4) in a subject in need thereof, said method comprising contacting the CCR4 in said subject with the compound of any one of claims 69 to 72 .
74 . The method of claim 73 , wherein the cancer is non-small cell lung cancer, head and neck squamous cell carcinoma, gastric cancer or lymphoma.
75 . The method of claim 73 , further comprising administering a second therapeutic agent.
76 . The method of claim 75 , wherein the second therapeutic agent is a chemotherapeutic or anticancer agent.
77 . The method of claim 76 , wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumour antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an oestrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5.alpha.-reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an agent used in antisense therapy, an anti-ras antisense, an agent used in a gene therapy, an immunotherapeutic agent, or an antibody.
78 . The method of claim 76 , wherein the chemotherapeutic agent or anticancer agent is an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4 or an agonistic antibody of CD137 (4-1BB).
79 . The method of claim 76 , wherein the chemotherapeutic agent or anticancer agent is pembrolizumab.